Lilly's retatrutide hits Phase 3 endpoints in TRIUMPH-2 and TRIUMPH-3 obesity trials 12 days ago Eli Lilly announced positive topline results on 23 July 2026 from two further Phase 3 trials of retatrutide, its investigational once-weekly triple agonist targeting the GIP, GLP-1 and glucagon receptors, in adults with obesity
Piana hoped to make a meaningful difference in the world by giving these high achievers the nutritional support they need to feel and function at their best, thus helping them achieve their goals and become the best possible version of themselves
Recent Findings Preliminary data suggest that GLP-1 RA can modulate crucial pathways in the pathogenesis of IBD, such as chronic inflammation circuits, intestinal tight junctions, and gut microbiome dysbiosis, setting the stage for human trials to investigate the role of these agents in the treatment of IBD among people with or without diabetes and obesity
For Williams, turning to weight-loss medications wasn't about "pushing harder," it was about being able to "live her best life" and be around for her daughters Alexis Olympia and Adira River, who she shares with husband Alexis Ohanian
Orforglipron improved A1C more than oral semaglutide, with an A1C drop of 1.71%1.91% compared to 1.23%1.47%
The retatrutide peptide dosage chart maps out these progression steps, and the dosage calculator helps you determine exact injection volumes for each dose level based on your vial concentration
